Ortho-McNeil sued over death of patient using Evra patch
US law firm Parker & Waichman says that it has filed suit against Ortho-McNeil Pharmaceutical, a division of Johnson & Johnson, on behalf of a 33-year-old woman and her husband. The woman allegedly suffered a bilateral pulmonary embolism and deep venous thrombosis after using the firm's Ortho Evra (norelgestromin and ethinyl estradiol) contraceptive patch for two months. The suit was filed in the US District Court for the District of New Jersey in Newark, New Jersey.
P&W notes that, on November 10, 2005, Ortho McNeil, in conjunction with the US Food and Drug Administration, issued a warning about the increased risks of blood clots associated with Ortho Evra. In this, the company admitted for the first time that women who use the patch will be exposed to up to 60% more estrogen than they would if they were taking a birth control pill with 35mcg of estrogen. The patch is only intended to deliver 20mcg of estrogen, says P&W.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze